MTAP DELETION
Clinical trials for MTAP DELETION explained in plain language.
Never miss a new study
Get alerted when new MTAP DELETION trials appear
Sign up with your email to follow new studies for MTAP DELETION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat cancers: drug combo targets genetic weakness
Disease control Recruiting nowThis study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …
Matched conditions: MTAP DELETION
Phase: PHASE1, PHASE2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New hope for Hard-to-Treat cancers: first human trial of PEP08 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…
Matched conditions: MTAP DELETION
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC